Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia
Launched by FHI 360 · Sep 16, 2014
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
We conducted a randomized controlled trial and enrolled 500 HIV-negative men aged 18-49 years at 3 clinics. Participants were randomized to 1 of 2 study arms (Standard Sizing arm vs Modified Sizing arm) in a 1:1 ratio. All 14 adult ShangRing sizes (40-26 mm inner diameter, each varying by 1 mm) were available in the Standard Sizing arm; the Modified Sizing arm used every other size (40, 38, 36, 34, 32, 30, 28 mm inner diameter). Each participant was scheduled for 2 follow-up visits: the removal visit (day 7 after placement) and the healing check visit (day 42 after placement), when they wer...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Must be aged 18 to 49 years;
- • Must be HIV-uninfected per same-day routine voluntary testing at the clinic;
- • Must be uncircumcised (on examination);
- • Must be in good general health, at the discretion of the clinician;
- • Must be free of genital ulcerations or other visible signs of STI (on examination);
- • Must be able to understand study procedures, and agree to abide by them including the follow-up visit schedule;
- • Must freely consent to participate in the study and sign a written informed consent form;
- • Must provide full contact information including cell phone number, address, and other locator information.
- Exclusion Criteria:
- • Has an active genital infection upon visual inspection;
- • Has an anatomic abnormality (e.g. phimosis or hypospadias) that contraindicates ShangRing MMC;
- • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid; or
- • Has a self-reported medical condition that would be a contraindication for elective surgery, e.g. hemophilia, extreme obesity, poorly controlled diabetes, sickle cell anemia
- • Has a self-reported allergy or sensitivity to lidocaine or other local
- • Is not available to be circumcised on the same day as screening.
About Fhi 360
FHI 360 is a nonprofit organization dedicated to improving lives worldwide through integrated and evidence-based approaches in health, education, and development. With a strong emphasis on research and innovation, FHI 360 conducts clinical trials that aim to advance public health outcomes, particularly in areas such as reproductive health, infectious diseases, and health systems strengthening. By collaborating with governments, NGOs, and local communities, FHI 360 strives to implement effective solutions that address complex global challenges, ensuring that interventions are sustainable and culturally appropriate. Their commitment to rigorous scientific inquiry and ethical standards positions them as a trusted leader in the field of global health research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lusaka, , Zambia
Lusaka, , Zambia
Patients applied
Trial Officials
Robert Zulu, MD
Principal Investigator
University Teaching Hospital
Paul Feldblum, PhD
Principal Investigator
FHI 360
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials